Raven StealthCo - Scientist/Senior Scientist, Protein Engineering and Discovery Biology

About Raven: We are Raven, RA Capital’s healthcare incubator. From discovery to delivery, whether we incubate, accelerate or rejuvenate, Raven’s goal is to turn scientific breakthroughs into transformative therapies and get them quickly, safely and efficiently to the patients that need them most. Raven’s experienced scientists, operators, and healthcare innovators have deep sector expertise across therapeutics, diagnostics, devices and services. They have brought hundreds of therapeutics into development, managed hospital systems, optimized clinical trials and navigated payor and regulatory systems to deliver patient impact - and they are ready to work with you. About RA Capital: Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our TechAtlas internal research division, and Raven, RA Capital’s company building team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 150 employees and over $10 billion in assets under management. Company Background We are a well-funded, stealth-mode biotechnology focused on next generation oligo-based modalities targeting tissues beyond the liver, muscle, and kidney. We are building a platform to deliver oligos with high precision to previously untargeted cells, while focused on “undruggable” genes, alone or in combination with previously validated targets. Many of our targets carry "pipeline-in-a-drug" potential: a single gene or protein with meaningful biological effects across multiple disease areas. Headquartered in Cambridge, Massachusetts, the company was incubated in RA Capital’s venture group (Raven) and is led by an experienced CEO. After a robust incubation and vetting process, Raven StealthCo was launched and funded by RA Capital. The company’s therapeutic areas of interest lie outside commonly targeted cells and tissues, and represent multi-billion-dollar markets that are continuing to grow as the population ages. Our initial focus is creating transformational therapies to treat diseases, but given the platform potential, we have longer-term ambitions to address healthy aging. These targets are backed by strong biological and genetic evidence but have historically resisted small molecule and biologic approaches. Raven StealthCo is moving quickly to address multiple disease indications at scale and with significant market potential. Opportunity We are in the discovery stage and will invest heavily in our emerging platform for oligonucleotide delivery. Our disease focus offers strong translatability from animal models to humans, which provides a potentially rapid and efficient path to the clinic. Given our recent funding and commitment to building a first-in-class platform, we are recruiting is seeking a Senior Scientist to join our Protein Engineering and Discovery Biology group. This individual will design and execute in vitro assays to characterize antibody candidates across the discovery and engineering pipeline by generating the binding, functional, and biophysical data that drive lead selection and optimization. The ideal candidate combines deep knowledge of antibody structure and function with hands-on expertise in cell-based assay development, cell culture, and protein analytics, and is comfortable working at the interface of protein engineering and cell biology. Responsibilities for the Senior Scientist include: Design, execute, and interpret binding assays (ELISA, surface plasmon resonance/SPR, bio-layer interferometry/BLI, flow cytometry) to characterize antibody affinity, kinetics, and specificity against target antigens. Develop and run cell-based internalization assays to assess antibody trafficking and receptor-mediated uptake. Design and execute cell-based functional assays to assess receptor agonism or antagonism including dose-response and mechanism-of-action studies. Maintain and expand mammalian cell culture capabilities including generation and maintenance of engineered cell lines used in assay development. Perform cell line characterization, including receptor/target expression profiling and phenotypic analysis to support assay design and data interpretation. Develop and execute cell signaling assays (e.g., reporter gene assays, phospho-flow cytometry, Western blot, or other signaling readouts) to evaluate antibody pharmacology. Conduct protein analytics (e.g., SEC-HPLC, SDS-PAGE, concentration and purity determination) to support antibody characterization and quality assessment. Apply working knowledge of antibody structure-function relationships to inform engineering strategies and assay design. Perform and interpret antibody biophysical characterization studies (e.g., thermal stability, aggregation propensity, binding kinetics) to support developability assessment. Analyze, interpret, and present data clearly to cross-functional project teams; maintain accurate and complete experimental records. Collaborate closely with protein engineering, discovery biology, and analytical teams to advance candidates through the discovery pipeline. Contribute to the design of assay strategies for new programs and help troubleshoot and optimize existing assay platforms. Bring in new methods, technologies, and vendors where existing approaches fall short, and operationalize methods once established: robust, documented, transferable assays with defined controls, acceptance criteria, and performance tracking Help build the lab (procurement, installation, equipment qualification), train future team members, and buil